Gravidez, Aleitamento e Fármacos em Dermatologia: Tratamento Tópico

Artur César; Filomena Azevedo; Alberto Mota

doi:10.29021/spdv.75.1.714

Artur César Serviço de Dermatologia e Venereologia/Dermatology Department, Centro Hospitalar São João, Porto, Portugal; Faculdade de Medicina, Universidade do Porto/Medical School, Oporto University, Porto, Portugal
Filomena Azevedo Serviço de Dermatologia e Venereologia/Dermatology Department, Centro Hospitalar São João, Porto, Portugal
Alberto Mota Serviço de Dermatologia e Venereologia/Dermatology Department, Centro Hospitalar São João, Porto, Portugal; Faculdade de Medicina, Universidade do Porto/Medical School, Oporto University, Porto, Portugal

DOI: https://doi.org/10.29021/spdv.75.1.714

Palavras-chave: Agentes Dermatológicos, Complicações da Gravidez/tratamento, Doenças de Pele /tratamento, Efeitos secundários Relacionados com Medicamentos e Reacções Adversas, Gravidez.

Resumo

O crescente número de fármacos empregues na prática dermatológica e venereológica exige do dermatologista um conhecimento atualizado relativo à sua segurança. No caso particular de mulheres grávidas ou que amamentem, a decisão sobre se se deve ou não tratar com um determinado fármaco deve basear-se numa avaliação ponderada dos benefícios para a saúde materna e dos riscos potenciais para o bem-estar fetal ou do lactente. Quando estas doentes necessitam terapêuticas tópicas ou sistémicas, a maioria pode ser adequadamente tratada com opções consideradas seguras e eficazes. Esta segunda parte deste artigo aborda os dados mais recentes relativos à segurança de alguns dos medicamentos tópicos mais comummente usados em contexto dermatológico, na mulher em idade fértil.

Downloads

Não há dados estatísticos.

Referências

Corton MM, Leveno K, Bloom S, Hauth J, Rouse D, Spong

C. Williams Obstetrics: 23rd ed. New York: McGraw Hill

Professional; 2009.

The Food and Drug Administration. Content and Format

of Labeling for Human Prescription Drug and Biological

Products; Requirements for Pregnancy and Lactation Labeling

[Internet]. 2008 [cited 2016 Nov 7] Available from:

https://federalregister.gov/a/E8-11806.

Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen

SA, Lammer EJ, et al. Maternal corticosteroid use and

orofacial clefts. Am J Obstet Gynecol. 2007;197:585.

e1-7; discussion 683-4, e1-7.

Chi C-C, Wang S-H, Wojnarowska F, Kirtschig G, Davies

E, Bennett C. Safety of topical corticosteroids in pregnancy.

Cochrane Database Syst Rev. 2015; CD007346.

Chi C-C, Kirtschig G, Aberer W, Gabbud J-P, Lipozenčić

J, Kárpáti S, et al. Evidence-based (S3) guideline on topical

corticosteroids in pregnancy. Br J Dermatol. 2011;

:943-52.

Hviid A, Mølgaard-Nielsen D. Corticosteroid use

during pregnancy and risk of orofacial clefts.

CMAJ.2011;183:796-804.

Brás S, Mendes-Bastos P, Oliveira A, Amaro C. Alterações

fisiológicas e dermatoses específicas da gravidez. Rev Soc

Port Dermatol Venereol. 2016; 73: 413-23.

Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen

SA, Werler MM, et al. Corticosteroid use and risk of orofacial

clefts. Birt Defects Res A Clin Mol Teratol. 2014;

:499-506.

Chi C-C, Wang S-H, Mayon-White R, Wojnarowska F.

Pregnancy outcomes after maternal exposure to topical

corticosteroids: a UK population-based cohort study.

JAMA Dermatol. 2013; 149:1274-80.

Kulski JK, Hartmann PE. Changes in the concentration of

cortisol in milk during different stages of human lactation.

Aust J Exp Biol Med Sci. 1981; 59:769-78.

Hale TW, Hartmann PE. Hale & Hartmann’s Textbook of

Human Lactation. London: Hale Publishing; 2007.

Butler DC, Heller MM, Murase JE. Safety of dermatologic

medications in pregnancy and lactation: Part II. Lactation.

J Am Acad Dermatol. 2014;70:417.e1-10; quiz 427.

Schaefer C, Peters PWJ, Miller RK. Drugs During Pregnancy

and Lactation: Treatment Options and Risk Assessment.

Oxoford: Academic Press; 2014.

Gouraud A, Bernard N, Millaret A, Bruel M, Paret N, Descotes

J, et al. Follow-up of tacrolimus breastfed babies.

Transplantation. 2012;94:e38-40.

Camera G, Pregliasco P. Ear malformation in baby born

to mother using tretinoin cream. Lancet.1992; 339:687.

Lipson AH, Collins F, Webster WS. Multiple congenital

defects associated with maternal use of topical tretinoin.

Lancet. 1993; 341:1352-3.

Willhite CC, Sharma RP, Allen PV, Berry DL. Percutaneous

retinoid absorption and embryotoxicity. J Invest Dermatol.

; 95:523-9.

Jick SS, Terris BZ, Jick H. First trimester topical tretinoin

and congenital disorders. Lancet.1993; 341:1181-2.

Leachman SA, Reed BR. The use of dermatologic drugs in

pregnancy and lactation. Dermatol Clin. 2006; 24:167-

, vi.

Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy

and Lactation: A Reference Guide to Fetal and Neonatal

Risk. Philadelphia: Lippincott Williams & Wilkins; 2011.

Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics

and drug metabolism of tazarotene: a

novel topical treatment for acne and psoriasis. Clin

Pharmacokinet. 1999; 37:273-87.

Menter A. Pharmacokinetics and safety of tazarotene. J

Am Acad Dermatol.2000; 43:S31–5.

Uchiyama H, Suzuki T, Koike Y, Ono M, Shirakawa K,

Nagata M, et al. Reproductive and developmental toxicity

studies of calcipotriol (MC903):(4) - A perinatal and

postnatal study in rats by subcutaneous administration. J

Toxicol Sci. 1996; 21 Suppl 2:439-55.

Bangsgaard N, Rørbye C, Skov L. Treating psoriasis during

pregnancy: safety and efficacy of treatments. Am J

Clin Dermatol. 2015; 16:389-98.

Rothberg AD, Pettifor JM, Cohen DF, Sonnendecker EW,

Ross FP. Maternal-infant vitamin D relationships during

breast-feeding. J Pediatr. 1982; 101:500-3.

Springer DL, Poston KA, Mahlum DD, Sikov MR. Teratogenicity

following inhalation exposure of rats to a high-

-boiling coal liquid. J Appl Toxicol.1982; 2:260-4.

Franssen ME, van der Wilt GJ, de Jong PC, Bos RP, Arnold

WP. A retrospective study of the teratogenicity of dermatological

coal tar products. Acta Derm Venereol. 1999;

:390-1.

Scheepers PT, van Houtum JL, Anzion RB, Harder R, Bos

RP, van der Valk PG. Uptake of pyrene in a breast-fed

child of a mother treated with coal tar. Pediatr Dermatol.

; 26:184-7.

American Academy of Pediatrics Committee on Drugs.

Transfer of drugs and other chemicals into human milk.

Pediatrics. 2001; 108:776-89.

Al-jedai Ahmed H., Balhareth SS, Algain RA. Assessment

of foetal risk associated with 93 non-US-FDA approved

medications during pregnancy. Saudi Pharm J. 2012;

:287-99.

McKelvy JF, LeBlanc P, Laudes C, Perrie S, Grimm-Jorgensen

Y, Kordon C. The use of bacitracin as an inhibitor of

the degradation of thyrotropin releasing factor and luteinizing

hormone releasing factor. Biochem Biophys Res

Commun. 1976; 73:507-15.

Patthy A, Gráf L, Kenessey A, Székely JI, Bajusz S. Effect

of bacitracin on the biodegradation of beta-endorphin.

Biochem Biophys Res Commun. 1977; 79:254-9.

Hale EK, Pomeranz MK. Dermatologic agents during

pregnancy and lactation: an update and clinical review.

Int J Dermatol. 2002; 41:197-203.

GlaxoSmithKline. Prescribing information BACTROBAN®

Cream [Internet]. [cited 2016 Jul 14];Available from:

https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/

US/en/Prescribing_Information/Bactroban_

Cream/pdf/BACTROBAN-CREAM.PDF

Murase JE, Heller MM, Butler DC. Safety of dermatologic

medications in pregnancy and lactation: Part I. Pregnancy.

J Am Acad Dermatol. 2014; 70:401.e1-14; quiz 415.

Pulkkinen MO, Willman K. Reduction of maternal estrogen

excretion by neomycin. Am J Obstet Gynecol. 1973;

:1153.

Mavrogenis S, Urban R, Czeizel AE, Acs N. Maternal

risk factors in the origin of isolated hypospadias: a

population-based case-control study. Congenit Anom.

; 54:110-5.

Mactal-Haaf C, Hoffman M, Kuchta A. Use of anti-infective

agents during lactation, Part 3: Antivirals, antifungals,

and urinary antiseptics. J Hum Lact. 2001; 17:160-6.

Brent NB. Thrush in the breastfeeding dyad: results of a

survey on diagnosis and treatment. Clin Pediatr. 2001;

:503-6.

Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier

C. Antifungal drugs during pregnancy: an updated

review. J Antimicrob Chemother. 2015; 70:14-22.

Johnstone HA, Marcinak JF. Candidiasis in the breastfeeding

mother and infant. J Obstet Gynecol Neonatal Nurs.

; 19:171-3.

Moudgal VV, Sobel JD. Antifungal drugs in pregnancy: a

review. Expert Opin Drug Saf. 2003; 2:475-83.

Roos TC, Alam M, Roos S, Merk HF, Bickers DR. Pharmacotherapy

of ectoparasitic infections. Drugs. 2001;

:1067-88.

Scott GR, Chosidow O, IUSTI/WHO. European guideline

for the management of scabies, 2010. Int J STD AIDS.

; 22:301-3.

Angel TA, Nigro J, Levy ML. Infestations in the pediatric

patient. Pediatr Clin North Am. 2000; 47:921-35, viii.

Rojansky N, Fasouliotis SJ, Ariel I, Nadjari M. Extreme

caudal agenesis. Possible drug-related etiology? J Reprod

Med. 2002; 47:241-5.

Smorlesi C, Caldarella A, Caramelli L, Di Lollo S, Moroni

F. Topically applied minoxidil may cause fetal malformation:

a case report. Birt Defects Res A Clin Mol Teratol.

; 67:997-1001.

Shapiro J. Safety of topical minoxidil solution: a one-

-year, prospective, observational study. J Cutan Med Surg.

; 7:322-9.

Mahé A, Perret JL, Ly F, Fall F, Rault JP, Dumont A. The cosmetic

use of skin-lightening products during pregnancy

in Dakar, Senegal: a common and potentially hazardous

practice. Trans R Soc Trop Med Hyg. 2007; 101:183-7.

Krasavage WJ, Blacker AM, English JC, Murphy SJ. Hydroquinone:

a developmental toxicity study in rats. Fundam

Appl Toxicol. 1992; 18:370-5.

Wester RC, Melendres J, Hui X, Cox R, Serranzana S, Zhai

H, et al. Human in vivo and in vitro hydroquinone topical

bioavailability, metabolism, and disposition. J Toxicol Environ

Health A. 1998; 54:301-17.

Goldberg D, Maloney M. Dermatologic surgery and cosmetic

procedures during pregnancy and the post-partum

period. Dermatol Ther. 2013; 26:321-30.

Bachrach LK, Burrow GN, Gare DJ. Maternal-fetal absorption

of povidone-iodine. J Pediatr. 1984; 104:158-9.

Casteels K, Pünt S, Brämswig J. Transient neonatal hypothyroidism

during breastfeeding after post-natal maternal

topical iodine treatment. Eur J Pediatr. 2000;

:716-7.

Moore PA. Selecting drugs for the pregnant dental patient.

J Am Dent Assoc. 1998; 129:1281-6.

Santos AC, Pedersen H, Harmon TW, Morishima HO,

Finster M, Arthur GR, et al. Does pregnancy alter the systemic

toxicity of local anesthetics? Anesthesiology. 1989;

:991-5.

Suresh L, Radfar L. Pregnancy and lactation. Oral Surg

Oral Med Oral Pathol Oral Radiol Endod. 2004; 97:672-

Sweeney SM, Maloney ME. Pregnancy and dermatologic

surgery. Dermatol Clin. 2006; 24:205-14, vi.

Rieken SE, Terezhalmy GT. The pregnant and breast-feeding

patient. Quintessence Int. 1985 2006; 37:455-68.

De Oliveira Monteiro E. Botulinum toxin and pregnancy.

Skinmed. 2006; 5:308.

Tan M, Kim E, Koren G, Bozzo P. Botulinum toxin type A in

pregnancy. Can Fam Physician. 2013; 59:1183-4.

Aranda MA, Herranz A, del Val J, Bellido S, García-Ruiz P.

Botulinum toxin A during pregnancy, still a debate. Eur J

Neurol. 2012; 19:e81-2.

Li Yim JFT, Weir CR. Botulinum toxin and pregnancy-a

cautionary tale. Strabismus. 2010; 18:65-6.

Paul M. Controversy: botulinum toxin in pregnancy. J

Cutan Aesthetic Surg. 2009; 2:4-5.

Polo JM, Martin J, Berciano J. Botulism and pregnancy.

Lancet. 1996; 348:195.

Robin L, Herman D, Redett R. Botulism in a pregnant

women. N Engl J Med. 1996; 335:823-4.

St Clair EH, DiLiberti JH, O’Brien ML. Letter: Observations

of an infant born to a mother with botulism. J Pediatr.

; 87:658.

Morrison GA, Lang C, Huda S. Botulism in a pregnant

intravenous drug abuser. Anaesthesia. 2006; 61:57-60.

Magri K, Bresson V, Barbier C. Botulism and pregnancy.

Biol Reprod 2006; 35:624-6.

Middaugh J. Botulism and breast milk. N Engl J Med.

; 298:343.

Babalola O, Strober BE. Management of psoriasis in

pregnancy. Dermatol Ther. 2013; 26:285-92.

El-Saie LT, Rabie AR, Kamel MI, Seddeik AK, Elsaie ML.

Effect of narrowband ultraviolet B phototherapy on serum

folic acid levels in patients with psoriasis. Lasers Med Sci.

; 26:481-5.

Park KK, Murase JE. Narrowband UV-B phototherapy during

pregnancy and folic acid depletion. Arch Dermatol.

; 148:132-3.

Juzeniene A, Stokke KT, Thune P, Moan J. Pilot study of

folate status in healthy volunteers and in patients with

psoriasis before and after UV exposure. J Photochem

Photobiol B. 2010; 101:111-6.

Gunnarskog JG, Källén AJ, Lindelöf BG, Sigurgeirsson

B. Psoralen photochemotherapy (PUVA) and pregnancy.

Arch Dermatol. 1993; 129:320-3.

Stern RS, Lange R. Outcomes of pregnancies among

women and partners of men with a history of exposure

to methoxsalen photochemotherapy (PUVA) for the treatment

of psoriasis. Arch Dermatol. 1991; 127:347-50.

Madan RK, Levitt J. A review of toxicity from topical salicylic

acid preparations. J Am Acad Dermatol. 2014;

:788-92.

Larsson KS, Bostroem H. Teratogenic actions of salicylates

related to the inhibition of mucopolysaccharide synthesis.

Acta Paediatr Scand. 1965; 54:43-8.

Täuber U, Weiss C, Matthes H. Percutaneous absorption

of azelaic acid in humans. Exp Dermatol. 1992; 1:176-9.

Akhavan A, Bershad S. Topical acne drugs: review of clinical

properties, systemic exposure, and safety. Am J Clin

Dermatol. 2003; 4:473-92.

Lopaschuk CC. New approach to managing genital

warts. Can Fam Physician. 2013; 59:731-6.

Ciavattini A, Tsiroglou D, Vichi M, Di Giuseppe J, Cecchi

S, Tranquilli AL. Topical Imiquimod 5% cream therapy

for external anogenital warts in pregnant women: report

of four cases and review of the literature. J Matern-Fetal

Neonatal. 2012; 25:873-6.

Stricker RB, Elswood BF. Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS. Immunol Lett. 1991; 29:191-6.